Head-to-head evidence
INV-202 vs INV-347
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: CB1 receptor · full Obesity pipeline
INV-202
Developed by Inversago Pharma and partners
NCT05891834 · Phase 2 · completed
Randomized, double-blind Phase 1b trial (n=54) demonstrating significant weight loss with peripheral CB1 inverse agonist (Lancet Diabetes Endocrinol 2025).
INV-347
Developed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07153172 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: INV-202's landscape · INV-347's landscape